Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143104 · ClinicalTrials.gov registry record · Phase 2
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
A Phase 2 study of Diabetes Mellitus, Type 1, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT00143104 is a Phase 2 study of Diabetes Mellitus, Type 1 that has completed, run by Pfizer. The registered enrollment target is 20 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00143104, a Phase 2 study of Diabetes Mellitus, Type 1, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.
Conditions Studied
Interventions
- DRUG Inhaled insulin
Study Locations (3)
Arizona
- Pfizer Investigational Site - Glendale
California
- Pfizer Investigational Site - Fresno
Texas
- Pfizer Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143104
The ClinicalTrials.gov registry entry for NCT00143104 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which Inhaled insulin is the first listed.
NCT00143104 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, California, Texas.
Frequently Asked Questions
What is clinical trial NCT00143104 about?
NCT00143104 is a clinical study titled "To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.". To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.
What is the current status of trial NCT00143104?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2004-12. Estimated completion is 2006-10.
What conditions does trial NCT00143104 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT00143104?
The interventions under investigation include: Inhaled insulin (DRUG).
Who is sponsoring clinical trial NCT00143104?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00143104 being conducted?
This trial has 3 study locations across Arizona, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
RECRUITING · Phase 2
-
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
ACTIVE NOT RECRUITING · Phase 2
-
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
ACTIVE NOT RECRUITING · Phase 2
-
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.